Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. TALVEY (talquetamab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

TALVEY (talquetamab)

Medicine - Posted on Jul 15 2024
Active substance (DCI)
  • talquetamab
history (2)
  • 6/26/24

    TALVEY (talquetamab) - Multiple myeloma

    Summary of opinion Favourable opinion for reimbursement in the indication “As monotherapy for the treatment of adult patient...
    CAV :
    54321
    icône flèche
  • 5/23/24

    TALVEY (talquetamab) - Myélome multiple

    Autorisation d’accès précoce refusée à la spécialité TALVEY (talquetamab) dans l’indication « en monothérapie pour le traite...
    icône flèche
Technical information
ATC code
  • L01FX29
Manufacturer
JANSSEN-CILAG
Presentation

TALVEY 2 mg/ml, solution injectable
1 flacon en verre de 1,5 ml (CIP : 34009 550 971 6 7)

TALVEY 40 mg/ml, solution injectable
1 flacon en verre de 1 ml (CIP : 34009 550 971 7 4)

All our publications
    Drug therapy Genital cancers Hematologic cancers Male genital diseases Medical imaging

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
Jtv4BkDJ8JSg4fC0